Pharmacogenetics of antiretroviral therapy
INTRODUCTION: Human genetic testing is rapidly entering into most medical disciplines, mainly as a way to predict hereditary conditions including predisposition to cancers or degenerative diseases. Another area of interest for human genomics is to ascertain the therapeutic effect and prevent potential toxicities and/or drug-drug interactions of medication.
AREAS COVERED: Several human genotypes have been associated with differences in the metabolism and transport of antiretroviral agents that ultimately affect drug exposure. The accelerated discovery of new gene mutations and polymorphisms that influence the effects of antiretroviral drugs provides a unique opportunity for a personalized medicine approach in the management of lifelong HIV therapy.
EXPERT OPINION: Integration of human genomic screening into HIV clinical management will be cost-effective, maximizing the benefit of drugs with the lowest risk of side effects for a given patient.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Expert opinion on drug metabolism & toxicology - 10(2014), 8 vom: 16. Aug., Seite 1119-30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barreiro, Pablo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abacavir |
|---|
| Anmerkungen: |
Date Completed 02.03.2015 Date Revised 19.11.2015 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1517/17425255.2014.930128 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM239295129 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM239295129 | ||
| 003 | DE-627 | ||
| 005 | 20231224115631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1517/17425255.2014.930128 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0797.xml |
| 035 | |a (DE-627)NLM239295129 | ||
| 035 | |a (NLM)24941049 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barreiro, Pablo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetics of antiretroviral therapy |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.03.2015 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Human genetic testing is rapidly entering into most medical disciplines, mainly as a way to predict hereditary conditions including predisposition to cancers or degenerative diseases. Another area of interest for human genomics is to ascertain the therapeutic effect and prevent potential toxicities and/or drug-drug interactions of medication | ||
| 520 | |a AREAS COVERED: Several human genotypes have been associated with differences in the metabolism and transport of antiretroviral agents that ultimately affect drug exposure. The accelerated discovery of new gene mutations and polymorphisms that influence the effects of antiretroviral drugs provides a unique opportunity for a personalized medicine approach in the management of lifelong HIV therapy | ||
| 520 | |a EXPERT OPINION: Integration of human genomic screening into HIV clinical management will be cost-effective, maximizing the benefit of drugs with the lowest risk of side effects for a given patient | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a abacavir | |
| 650 | 4 | |a antiretrovirals | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a tenofovir | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 700 | 1 | |a Fernández-Montero, José Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a de Mendoza, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Labarga, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Vincent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug metabolism & toxicology |d 2005 |g 10(2014), 8 vom: 16. Aug., Seite 1119-30 |w (DE-627)NLM164308237 |x 1744-7607 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2014 |g number:8 |g day:16 |g month:08 |g pages:1119-30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1517/17425255.2014.930128 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2014 |e 8 |b 16 |c 08 |h 1119-30 | ||